INNOCAN PHARMA Corp
INNPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.00 | -0.04 | 1.62 |
| FCF Yield | 0.03% | 3.01% | 0.97% | -1.15% |
| EV / EBITDA | -33.24 | -176.42 | 702.22 | 3,278.85 |
| Quality | ||||
| ROIC | -17.04% | 14.15% | -41.40% | 209.10% |
| Gross Margin | 90.75% | 88.42% | 91.26% | 81.63% |
| Cash Conversion Ratio | -0.01 | -2.18 | -1.61 | 10.50 |
| Growth | ||||
| Revenue 3-Year CAGR | 39.63% | 63.75% | 99.11% | 125.66% |
| Free Cash Flow Growth | -97.37% | 88.71% | 171.46% | 49.65% |
| Safety | ||||
| Net Debt / EBITDA | 4.09 | 61.02 | -110.07 | -416.50 |
| Interest Coverage | 0.00 | 99.00 | 163.00 | -306.33 |
| Efficiency | ||||
| Inventory Turnover | 0.26 | 0.31 | 0.23 | 0.30 |
| Cash Conversion Cycle | 357.23 | 272.50 | 379.39 | 295.58 |